Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Advanced or Metastatic Solid Tumor Malignancies

NCT01607905 is registered in ClinicalTrials.gov with Karyopharm Therapeutics Inc as lead sponsor.

NCT NCT01607905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01607905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Advanced or Metastatic Solid Tumor Malignancies
Lead sponsor
Karyopharm Therapeutics Inc
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2012
Completion date
March 15, 2016
Enrollment
192 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor